glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care ISPOR 2025: Exploring reasons for

Description

This interesting finding, occurring without weight loss, is consistent with preclinical and clinical studies showing weight-independent effects of GLP-1R agonism on liver steatosis 51,52,53

GLP-1 dose conversion chart and safe switching guide Navigating GLP-1 agonist conversions requires more than a simple chart

Thirty-six percent of patients in the first month of the Wegovy pill were new to GLP-1 therapy. Supporting GLP-1 users Supporting GLP-1 users may be done by adding such attributes as protein, fiber, electrolytes for hydration and portion size to product applications

The availability of semaglutide in different formulations, such as injections and oral tablets, provides patients with options that cater to their preferences

This rise may relate to emerging evidence of its metabolic efficacy and weight loss benefits, which could be influencing prescribing patterns among patients with PCOS (16)